Molecular Pharming for low and middle income countries
Interest in applications and benefits that Molecular Pharming might offer to Low and Middle Income Countries has always been a potent driver for the research discipline, and a major reason why many scientists entered the field. Although enthusiasm remains high, the reality is that such a game-changi...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2019
|
| _version_ | 1797077597648060416 |
|---|---|
| author | Murad, S Fuller, S Menary, J Moore, C Pinneh, E Szeto, T Hitzeroth, I Freire, M Taychakhoonavudh, S Phoolcharoen, W Ma, JK-C |
| author_facet | Murad, S Fuller, S Menary, J Moore, C Pinneh, E Szeto, T Hitzeroth, I Freire, M Taychakhoonavudh, S Phoolcharoen, W Ma, JK-C |
| author_sort | Murad, S |
| collection | OXFORD |
| description | Interest in applications and benefits that Molecular Pharming might offer to Low and Middle Income Countries has always been a potent driver for the research discipline, and a major reason why many scientists entered the field. Although enthusiasm remains high, the reality is that such a game-changing innovation would always take longer than traditional uptake of new technology in developed countries, and be complicated by external factors beyond technical feasibility. Excitingly, signs of increasing interest by LMICS in Molecular Pharming are now emerging. Here, three case studies from Thailand, South Africa and Brazil are used to identify some of the key issues when a new investment into Molecular Pharming manufacturing capacity is under consideration. At present, academic research is not necessarily addressing these issues. Only by understanding the concerns, can members of the academic community contribute to helping the development of Molecular Pharming for LMICs by focusing their research efforts appropriately. |
| first_indexed | 2024-03-07T00:20:22Z |
| format | Journal article |
| id | oxford-uuid:7c56b1a5-2b5e-4e06-8388-2590ca4817c2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:20:22Z |
| publishDate | 2019 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:7c56b1a5-2b5e-4e06-8388-2590ca4817c22022-03-26T20:56:28ZMolecular Pharming for low and middle income countriesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7c56b1a5-2b5e-4e06-8388-2590ca4817c2EnglishSymplectic ElementsElsevier2019Murad, SFuller, SMenary, JMoore, CPinneh, ESzeto, THitzeroth, IFreire, MTaychakhoonavudh, SPhoolcharoen, WMa, JK-CInterest in applications and benefits that Molecular Pharming might offer to Low and Middle Income Countries has always been a potent driver for the research discipline, and a major reason why many scientists entered the field. Although enthusiasm remains high, the reality is that such a game-changing innovation would always take longer than traditional uptake of new technology in developed countries, and be complicated by external factors beyond technical feasibility. Excitingly, signs of increasing interest by LMICS in Molecular Pharming are now emerging. Here, three case studies from Thailand, South Africa and Brazil are used to identify some of the key issues when a new investment into Molecular Pharming manufacturing capacity is under consideration. At present, academic research is not necessarily addressing these issues. Only by understanding the concerns, can members of the academic community contribute to helping the development of Molecular Pharming for LMICs by focusing their research efforts appropriately. |
| spellingShingle | Murad, S Fuller, S Menary, J Moore, C Pinneh, E Szeto, T Hitzeroth, I Freire, M Taychakhoonavudh, S Phoolcharoen, W Ma, JK-C Molecular Pharming for low and middle income countries |
| title | Molecular Pharming for low and middle income countries |
| title_full | Molecular Pharming for low and middle income countries |
| title_fullStr | Molecular Pharming for low and middle income countries |
| title_full_unstemmed | Molecular Pharming for low and middle income countries |
| title_short | Molecular Pharming for low and middle income countries |
| title_sort | molecular pharming for low and middle income countries |
| work_keys_str_mv | AT murads molecularpharmingforlowandmiddleincomecountries AT fullers molecularpharmingforlowandmiddleincomecountries AT menaryj molecularpharmingforlowandmiddleincomecountries AT moorec molecularpharmingforlowandmiddleincomecountries AT pinnehe molecularpharmingforlowandmiddleincomecountries AT szetot molecularpharmingforlowandmiddleincomecountries AT hitzerothi molecularpharmingforlowandmiddleincomecountries AT freirem molecularpharmingforlowandmiddleincomecountries AT taychakhoonavudhs molecularpharmingforlowandmiddleincomecountries AT phoolcharoenw molecularpharmingforlowandmiddleincomecountries AT majkc molecularpharmingforlowandmiddleincomecountries |